Risk factors and mechanisms of fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections

References

• Muratani T, Matsumoto T. Bacterial resistance to antimicrobials in urinary isolates. Int J Antimicrob Agents 2004;24: S28–31.
   PubMed Web of Science ®Google Scholar
• Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection 2008;36:41–5.
   PubMed Web of Science ®Google Scholar
• Shigemura K, Arakawa S, Miura T, Nakano Y, Tanaka K, Fujisawa M. Significance of fluoroquinolone-resistant Escherichia coli in urinary tract infections. Jpn J Infect Dis 2008;61:226–8.
   PubMed Web of Science ®Google Scholar
• Arslan H, Azap OK, Ergonul O, Timurkaynak F; Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005;56:914–8.
   PubMed Web of Science ®Google Scholar
• Nys S, Terporten PH, Hoogkamp-Korstanje JA, Stobberingh EE; Susceptibility Surveillance Study Group. Trends in antimicrobial susceptibility of Escherichia coli isolates from urology services in the Netherlands (1998–2005). J Antimicrob Chemother 2008;62:126–32.
   PubMedGoogle Scholar
• Muratani T, Matsumoto T. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae. Int J Antimicrob Agents 2006;28:S10–3.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Cho JK, Kim KS, Tak RB, Kim AR, Kim JW, . Fluoroquinolone resistance and gyrA and parC mutation Escherichia coli isolated from chicken. J Microbiol 2005;43: 391–7.
   PubMed Web of Science ®Google Scholar
• Sorlozano A, Gutierrez J, Jimenez A, de Dios Luna J, Martínez JL. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-β-lactamase producing Escherichia coli isolates. J Clin Microbiol 2007;45: 2740–2.
   PubMedGoogle Scholar
• Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003;47:3222–32.
   PubMed Web of Science ®Google Scholar
• Brown P, Ki M, Foxman B. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics 2005;23:1123–42.
   PubMed Web of Science ®Google Scholar
• Ulett KB, Benjamin WH Jr, Zhuo F, Xiao M, Kong F, Gilbert GL, . Diversity of group B Streptococcus serotypes causing urinary tract infection in adults. J Clin Microbiol 2009;47:2055–60.
   PubMed Web of Science ®Google Scholar
• Miura T, Tanaka K, Shigemura K, Nakano Y, Takenaka A, Fujisawa M. Levofloxacin-resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. Int J Urol 2008;15:457–9.
   PubMed Web of Science ®Google Scholar
• Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006;6:629–40.
   PubMed Web of Science ®Google Scholar
• Saito R, Kumita W, Sato K, Chida T, Okamura N, Moriya K, . Detection of plasmid-mediated quinolone resistance associated with qnrA in an Escherichia coli clinical isolate producing CTX-M-9 β-lactamase in Japan. Int J Antimicrob Agents 2007;29:597–611.
   PubMedGoogle Scholar
• Huotari K, Tarkka E, Valtonen V, Kolho E. Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis 2003;22:492–5.
   PubMedGoogle Scholar
• Chenia HY, Pillay B, Pillay D. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother 2006;58:1274–8.
   PubMed Web of Science ®Google Scholar
• Vila J, Ruiz J, Goñi P, De Anta MT. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1996;40:491–3.
   PubMed Web of Science ®Google Scholar
• Okumura R, Hirata T, Onodera Y, Hoshino K, Otani T, Yamamoto T, . Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2008;62: 98–104.
   PubMedGoogle Scholar
• Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996;40: 879–85.
   PubMed Web of Science ®Google Scholar
• Ozeki S, Deguchi T, Yasuda M, Nakano M, Kawamura T, Nishino Y, . Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections. J Clin Microbiol 1997;35:2315–9.
   PubMedGoogle Scholar
• Lin CY, Huang SH, Chen TC, Lu PL, Lin WR, Chen YH. Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates. J Microbiol Immunol Infect 2008;41:325–31.
   PubMedGoogle Scholar
• Nishino K, Nikaido E, Yamaguchi A. Regulation and physiological function of multidrug efflux pumps in Escherichia coli and Salmonella. Biochim Biophys Acta 2009;1794:834–43.
   PubMedGoogle Scholar
• Weigel LM, Steward CD, Tenover FC. GyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 1998;42: 2661–7.
   PubMedGoogle Scholar
• Marcusson LL, Frimodt-Møller N, Hughes D. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 2009;5:e1000541.
   PubMed Web of Science ®Google Scholar
• Everett MJ, Jin YF, Ricci V, Piddock LJ. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996;40:2380–6.
   PubMed Web of Science ®Google Scholar